Statement News

CONCORD, Calif.--(BUSINESS WIRE)--Following five months of stalled contract negotiations, UFCW 8-Golden State, along with UFCW Locals 5 and 648, announced a temporary extension of the strike deadline after the Federal Mediator overseeing talks recommended additional time for bargaining. Union negotiators agreed to delay the strike, originally set to begin at midnight, citing incremental progress toward a tentative agreement members can review and vote on. “This recognition of our pressure and m...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the following statement: Just before 6:00 p.m. ET today, the U.S. Food and Drug Administration (FDA) issued a press release announcing an investigation into the death of an eight-year-old Duchenne muscular dystrophy (Duchenne) patient who had received ELEVIDYS (delandistrogene moxeparvovec) gene therapy. The death of this patient was deemed unrela...

COPPELL, Texas--(BUSINESS WIRE)--GrabAGun Digital Holdings Inc. (“GrabAGun” or the “Company”) (NYSE:PEW), an online retailer of firearms, ammunition and related accessories, today provided the following statements applauding the Ninth Circuit’s ruling in Rhode v. Bonta, which struck down California’s ammunition background check law as unconstitutional. In a 2-1 decision, the appellate court ruled that California’s requirement for a background check before every ammunition purchase violates the...

WASHINGTON--(BUSINESS WIRE)--The ESOP Association urges U.S. Senate to promptly confirm Daniel Aronowitz as Assistant Secretary of Labor for EBSA....

NEW YORK--(BUSINESS WIRE)--Columbia University has reached an agreement with the United States Government to resolve multiple federal agency investigations into alleged violations of federal anti-discrimination laws. As part of the resolution, Columbia will pay a $200 million settlement over three years to the federal government. In addition, the University has agreed to settle investigations brought by the U.S. Equal Employment Opportunity Commission for $21 million. Importantly, the agreement...

TORONTO--(BUSINESS WIRE)--Over one hundred CUPE members from around the GTA gathered outside the Villa Charities owned property at the corner of Dufferin and Lawrence Avenue West to bolster the picket line of CUPE 5525. The 25 members of CUPE 5525 have been on strike since the 28th of May after negotiations to secure their first collective agreement broke down. Villa Colombo hired scab replacement workers and did not engage with the union’s bargaining team for weeks. The bolstered picket line b...

DALLAS--(BUSINESS WIRE)--MB2 Dental, the nation's first and largest dental partnership organization (DPO), reported strong progress across key business and community initiatives during the first half of 2025. The company's mid-year performance demonstrates a continued commitment to empowering dental professionals while advancing innovation, education, and service. Mid-Year Business Overview Total practices: 750+ Total number of practice owners: 775+ Total doctors: 1,700+ Total patients served:...

CHICAGO--(BUSINESS WIRE)--The release is a statement Ms. Pramaggiore has authorized Mark Herr Communications to make on her behalf after sentencing is completed....

TORONTO--(BUSINESS WIRE)--Sierra Metals Inc. (TSX: SMT | OTCQX: SMTSF | BVL: SMT) ("Sierra Metals" or the "Company") wishes to respond to the unfounded allegations made by Alpayana S.A.C. ("Alpayana") in its July 18, 2025 press release. Alpayana began its pursuit of Sierra Metals on December 16, 2024, by launching a hostile take-over for Sierra Metals at a bid price of CAD $0.85 per common share. The CAD $0.85 bid price was a 10% premium to the prior day closing price, a price that Alpayana kne...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the following statement: Shortly after 2:30 p.m. ET today, Sarepta received an informal request from the U.S. Food and Drug Administration (FDA) to voluntarily halt shipment of ELEVIDYS (delandistrogene moxeparvovec), our gene therapy for Duchenne muscular dystrophy (Duchenne), in the U.S. We first heard of this potential request earlier in the da...